Description

Sotalol Sandoz (sotalol hydrochloride) tablets 160 mg. №50

Ingredients

Active ingredient: Sotalol hydrochloride
Other ingredients: lactose monohydrate, maize starch, colloidal anhydrous silica, magnesium stearate, hypromellose, macrogol 4000, and titanium dioxide.

Dosage

Recommended dosage: The usual starting dose is 80 mg twice daily. Dosage may be increased gradually every 2-3 days based on response and tolerability. The maximum recommended dose is 160 mg twice daily.

Indications

Sotalol Sandoz tablets are indicated for the treatment of documented ventricular arrhythmias and certain types of atrial fibrillation or atrial flutter.

Contraindications

Do not use Sotalol Sandoz tablets if you have bronchial asthma, certain types of heart block, severe bradycardia, or uncontrolled heart failure. Consult your healthcare provider before use.

Directions

Take Sotalol Sandoz tablets orally with or without food as directed by your doctor. Do not skip doses or suddenly stop taking this medication without consulting your healthcare provider.

Scientific Evidence

Sotalol, the active ingredient in Sotalol Sandoz tablets, is a non-selective beta-blocker with Class III antiarrhythmic properties. It prolongs the action potential duration and refractory period in cardiac tissues, thereby suppressing abnormal rhythms. Studies have shown its efficacy in reducing the recurrence of ventricular arrhythmias and maintaining sinus rhythm in atrial fibrillation.

Additional Information

It is important to monitor heart rate and rhythm regularly while on Sotalol therapy. This medication may cause dizziness or fatigue; avoid driving or operating machinery if affected. Inform your doctor about all medications, including over-the-counter drugs and supplements, before starting Sotalol Sandoz.

Pharmacological Effects: Sotalol acts by blocking beta-adrenergic receptors, leading to a decrease in heart rate and contractility. Additionally, its potassium channel-blocking properties help in preventing re-entry mechanisms in arrhythmias.

Clinical Trials: Clinical trials have demonstrated the effectiveness of Sotalol in reducing the incidence of ventricular arrhythmias and maintaining sinus rhythm in atrial fibrillation. A study by Singh et al. (2015) showed a significant decrease in the number of ventricular tachycardia episodes with Sotalol treatment compared to placebo.